title: Intra-arterial cisplatin with concomitant radiation for advanced hypopharyngeal cancer.
abstract: OBJECTIVE
  The current study evaluated the efficacy of radiation and concomitant high-dose superselective intra-arterial cisplatin infusion (RADPLAT) for patients with advanced hypopharyngeal cancer.
  
  
  METHODS
  Retrospective, single-institutional study.
  
  
  METHODS
  Between February 2004 and October 2010, 43 patients with T2N0 or worse cancer were given superselective intra-arterial infusions of cisplatin (100-mg/m(2) or 75-mg flat dose per week) with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity and conventional external beam radiotherapy (60-66 Gy).
  
  
  RESULTS
  In total, three, seven, 21, and 12 patients were diagnosed with stage II, III, IVA, and IVB cancer, respectively. During the median follow-up period of 34 months, the 3-year overall survival, disease-specific survival, and progression-free survival rates for all patients were 52.2%, 68.2%, and 56.1%, respectively. The 3-year local control and laryngoesophageal dysfunction-free survival rates were 81.6% and 49.4%, respectively. No patient died because of treatment toxicity. Among grade IV toxicity, cerebral infarction (n = 1) and laryngeal necrosis (n = 1) resulting in laryngectomy were observed.
  
  
  CONCLUSIONS
  Despite being a single-institution experience, the results of the current study suggest that RADPLAT can achieve favorable survival rates and high rates of laryngeal preservation for patients with advanced hypopharyngeal cancers. Laryngoscope, 2012.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan. nomu-ken@asahikawa-med.ac.jp
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Nomura
authors.forename: Miki
authors.initials: M
authors.lastname: Takahara
authors.forename: Akihiro
authors.initials: A
authors.lastname: Katayama
authors.forename: Kan
authors.initials: K
authors.lastname: Kishibe
authors.forename: Isamu
authors.initials: I
authors.lastname: Kunibe
authors.forename: Akihiro
authors.initials: A
authors.lastname: Katada
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Hayashi
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Harabuchi
mesh_terms: D061605:Administration, Intravenous; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013885:Thiosulfates / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D013885:Thiosulfates; D002945:Cisplatin